Entering text into the input field will update the search result below

Novartis ups investment in Israeli stem cell firm Gamida Cell

Oct. 12, 2015 11:28 AM ETNovartis AG (NVS) StockNVSBy: Douglas W. House, SA News Editor
  • Novartis (NVS +0.2%) agrees to invest another $15M in Gamida Cell, a Jerusalem-based developer of stem cell therapies. The new investment, representing a 2.5% stake, will raise its total investment to $50M, or 17.5%. The deal could grow to $600M if Novartis exercises a buyout option that expires in 2016. It will invest an additional $10M if Gamida is successful in closing equity financing by the end of 2017.
  • Gamida intends to use the funds to initiate a Phase 3 clinical trial evaluating NiCord in blood cancers in mid-2016.
  • NiCord, an ex vivo expanded cell graft, is in development as an alternative to bone marrow transplant for patients who cannot find a donor with fully matched tissue.  It utilizes the company's proprietary NAM platform technology to expand cells from umbilical cord blood.

Recommended For You

More Trending News

About NVS Stock

SymbolLast Price% Chg
Market Cap
PE
Yield (TTM)
Rev Growth (YoY)
Prev. Close
Compare to Peers

Related Stocks

SymbolLast Price% Chg
NVS--
Novartis AG